Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat
Research output: Contribution to journal › Journal article › Research › peer-review
YKL-40 regulates vascular endothelial growth factors and induces tumor proliferation. We investigated YKL-40 before and after treatment with vorinostat in 31 polycythemia vera (PV) and 16 essential thrombocythemia (ET) patients. Baseline PV patient levels were 2 times higher than in healthy controls (P<0.0001) and 1.7 times higher than in ET (P=0.02). A significant correlation between YKL-40 at baseline and neutrophils, CRP, LDH, JAK2V617F and platelets in PV patients was observed, as well as a significantly greater reduction of YKL-40 levels in PV patients responding to therapy. YKL-40 might be a novel marker of disease burden and progression in myeloproliferative neoplasms.
| Original language | English |
|---|---|
| Journal | Leukemia Research |
| Volume | 38 |
| Issue number | 7 |
| Pages (from-to) | 816-821 |
| Number of pages | 6 |
| ISSN | 0145-2126 |
| DOIs | |
| Publication status | Published - Jul 2014 |
- Adipokines, Adult, Aged, Aged, 80 and over, C-Reactive Protein, Female, Histone Deacetylase Inhibitors, Humans, Hydroxamic Acids, Lectins, Male, Middle Aged, Polycythemia Vera, Thrombocythemia, Essential
Research areas
ID: 138381557